Transcriptional up-regulation of PHLDA1 by 17&#946;-estradiol in MCF-7 breast cancer cells by MARCHIORI, A.C. et al.
579
Braz J Med Biol Res 41(7) 2008
Up-regulation of PHLDA1 mRNA by 17ß-estradiol
www.bjournal.com.br
Transcriptional up-regulation of PHLDA1 by
17ß-estradiol in MCF-7 breast cancer cells
A.C. Marchiori, D.A. Casolari and M.A. Nagai
Disciplina de Oncologia, Departamento de Radiologia, Faculdade de Medicina, Universidade de São
Paulo, São Paulo, SP, Brasil
Correspondence to: M.A. Nagai, Disciplina de Oncologia, Departamento de Radiologia, FM-USP, Av. Dr.
Arnaldo, 455, 4° andar, 01246-903 São Paulo, SP, Brasil
Fax: +55-11-3069-7292. E-mail: nagai@usp.br
Most breast cancer risk factors are associated with prolonged exposure of the mammary gland to high levels of estrogens. The
actions of estrogens are predominantly mediated by two receptors, ERα and ERß, which act as transcription factors binding with
high affinity to estrogen response elements in the promoter region of target genes. However, most target genes do not contain
the consensus estrogen response elements, but rather degenerated palindromic sequences showing one or more mutations and
other ER-binding sites such as AP-1 and SP-1. Using the differential display reverse transcription-polymerase chain reaction
technique, our group identified several genes differentially expressed in normal tissue and in ER-positive and ER-negative
primary breast tumors. One of the genes shown to be down-regulated in breast tumors compared to normal breast tissue was
the PHLDA1 (Pleckstrin homology-like domain, family A, member 1). In the present study, we investigated the potential of
PHLDA1 to be regulated by estrogen via ER in MCF-7 breast cancer cells. The promoter region of PHLDA1 shows an imperfect
palindrome, an AP-1- and three SP-1-binding sites potentially regulated by estrogens. We also assessed the effects of 17ß-
estradiol on PHLDA1 mRNA expression in MCF-7 breast cancer cells. MCF-7 cells exposed to 10 nM 17ß-estradiol showed
more than 2-fold increased expression of the PHLDA1 transcripts compared to control cells (P = 0.05). The anti-estrogen ICI
182,780 (1 µM) inhibited PHLDA1 mRNA expression and completely abolished the effect of 10 nM 17ß-estradiol on PHLDA1
expression (P < 0.05), suggesting that PHLDA1 is regulated by estrogen via ER.
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Most breast cancer risk factors are associated with
prolonged exposure of the mammary gland to high levels of
estrogen (E2) (1). The biological effects of estrogen are
predominantly mediated by two distinct receptors, ERα and
ERß, which are ligand-activated transcription factors (2).
The estrogen receptors have similar structures, showing a
high degree of homology in the DNA-binding domain, the
most conserved region that contains two zinc finger motifs
(3). Estrogen receptors bind with high affinity to estrogen
response elements (EREs) in the promoter region of target
genes, interact with the basal transcription machinery and
regulate gene expression. The consensus ERE is a perfect
palindromic DNA motif consisting of two inverted sequences
of 5 bp separated by three nucleotides, 5'-GGTCAnnn
TGACC-3' (4). In the human genome, however, most pro-
moter regions of estrogen target genes do not contain the
consensus ERE, but contain degenerate palindromic se-
quences showing one or more mutations, ERE half-sites,
direct repeats of half-palindromes and other transcription
factor-binding sites such as AP-1, SP-1, NF-κB, C/EBP,
FoxA1, and octamers (4-6). ER also interacts with EREs
containing variation in a single base, although some nucleo-
tide substitutions can be more harmful than others (7). Some
symmetrical substitutions on each side of the palindrome
may more dramatically affect the interaction with the ER than
a unilateral replacement (7).
The presence of the ER and progesterone receptor in
breast tumors has been used as a prognostic indicator and
predictive factor of response to adjuvant hormonal thera-
py. However, a subgroup of ER-positive breast cancer
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patients either does not respond to hormonal therapy, or
becomes resistant to it (8). Over the last few years, differ-
ent molecular technologies that allow high throughput anal-
ysis of gene expression profiling have been used to identify
the gene expression signature associated with the hor-
mone-dependence of breast cancer that might improve our
understanding of ER-positive breast cancers and help
select therapy for individual patients.
Using the differential display reverse transcription-poly-
merase chain reaction technique, our group identified sev-
eral genes differentially expressed in primary breast tu-
mors regarding the presence or absence of ER and pro-
gesterone receptor, and a set of genes differentially ex-
pressed in normal and tumor tissues regardless ER status
(9). One of the genes found to be down-regulated in breast
tumors compared to normal breast tissue was the PHLDA1
(Pleckstrin homology-like domain, family A, member 1).
The PHLDA1 gene is located on chromosome 12q15-21.2
and encodes a protein of 262 amino acids that is co-
localized with FAK (10). The PHLDA1 protein contains
protein-protein interaction domains in its carboxy-terminal
region, such as proline-histidine and proline-glutamine
repeats, which may have a role in transcriptional activation
and may mediate apoptosis in T cell hybridomas and in
neuronal and melanoma cells (11-13).
Recently, using immunohistochemistry in tissue micro-
array containing a large series of samples, we demon-
strated that PHLDA1 expression is frequently down-regu-
lated in primary breast tumors and has a predictive prog-
nostic value (14). In the present study, we have investi-
gated the potential regulation of PHLDA1 by estrogen via
ER in MCF-7 breast cancer cells.
To assess the potential regulation of PHLDA1 by estra-
diol via ER, we performed a manual search of potential ER-
binding sites in the promoter region of the PHLDA1 gene.
The NCBI (www.ncbi.nlm.nih.gov) and USCU Genome
Bioinformatics (genome.uscs.edu) databases were used
to annotate the position of PHLDA1 in the genome and to
extract a 5’ flanking region from 2 kb upstream to 2 kb
downstream of the transcription start site or transcription
Figure 1. Structure of the human PHLDA1
gene located on chromosome 12q15 and its
partial promoter region (sequences 2 kb up-
stream to 2 kb downstream of the transcrip-
tion start site, TSS). The numbers shown on
the left indicate the nucleotide position rela-
tive to the transcription start site (+1). The
sequence of the PHLDA1 partial promoter
region was obtained from www.ensembl.org.
The sequences of the ATG start codon, im-
perfect palindrome, AP-1- and SP-1-binding
sites and TATA and GATA boxes are under-
lined and in bold. The exons are represented
in capital letters and the introns in the lower
case letters.
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binding site. The search for EREs and other transcription
factor-binding sites was performed using several publicly
available programs (Transfac 6.0, www.gene-regulation.
com) and Dragon Genome Explorer (research.i2.a-
star.edusg/promoter). We identified the presence of an
imperfect palindrome with two mutations separated by two
nucleotides at position -1522 (GCTCACTTGTCC) and di-
rect repetitions of half-EREs and half-palindromes spread
in the promoter region. Furthermore, the analysis revealed
the presence of an AP-1 site at -127 (GAGAGGA), three
SP-1 sites at -66 (GGGCGG), +547 (CCGCCC), +1743
(CCGCCC), a TATA box at -1261 (TATAAAA), and a
GATA-1 box at +1227 (GACAAG) (Figure 1). Next we
examined the effects of 17ß-estradiol and ICI 182,780 on
PHLDA1 mRNA expression in MCF-7 cells, a hormone-
responsive breast cancer cell line. The MCF-7 cell line was
acquired from the American Type Culture Collection (USA)
and cultured as described previously (15). For the experi-
ments, the cells were maintained in RPMI-1640 modified
medium, without phenol red, and supplemented with 5%
fetal bovine serum or 5% stripped fetal bovine serum, free
of steroids, for 48 h before the treatments. MCF-7 cells
were treated with 10 nM 17ß-estradiol (Sigma Chemical
Corporation, USA) or 1 µM ICI 182,780 (TOCRIS Bio-
sciences) alone or in combination for 2, 6, and 24 h. Anti-
estrogens, such as tamoxifen (selective estrogen modula-
tors) and ICI 182,780 (selective estrogen receptor down-
regulators), are used to investigate
whether or not the estrogen actions
are mediated by ER pathways. Since
tamoxifen also acts as an estrogen
agonist in some tissues, here we used
ICI 182,780 (fulvestrant), considered
to be a pure estrogen antagonist, which
binds to ER leading to its destabiliza-
tion and degradation (16). The con-
centrations of 17ß-estradiol (10 nM)
and ICI 182,780 (1 µM) used in our
experiments were the same as used in
several previous reports (17). The ex-
periments were performed in triplicate.
At each time point of drug treatment,
cells were harvested and total RNA
was isolated using the Illustra RNAspin
kit (GE Healthcare, UK). cDNA synthe-
sis was carried out using the High Ca-
pacity Archive kit (Applied Biosystems,
UK). Real time PCR was performed
using the SYBR Green kit (Applied
Biosystems, USA) following manufac-
turer recommendations. Real time PCR
products were processed with the GeneAmp 5700 Se-
quence Detector (PE Applied Biosystems, USA) as de-
scribed previously (14). The Student t-test was used for
statistical analysis and P ≤ 0.05 was considered to be
statistically significant.
Most of the human estrogen target genes identified so
far do not contain a perfect palindromic consensus se-
quence in their promoter regions (4). However, several
lines of evidence indicate that sequences of ERE half-sites
associated with SP-1 sites, direct repeats of ERE half-
sites, and EREs with different spacing between the palin-
dromic sequences also display estrogen responses (18,19).
Our analysis of the PHLDA1 promoter region revealed the
presence of several transcription factor binding sites in-
cluding one imperfect palindrome, direct repeats of half-
EREs, one AP1- and three SP1-binding sites, suggesting
that estrogen might play a role in the transcriptional regu-
lation of this gene. As shown in Figure 2, increased expres-
sion of PHLDA1 transcripts (more than 2-fold) was ob-
served in MCF-7 cells exposed to 10 nM 17ß-estradiol
compared to control cells (P = 0.05). PHLDA1 mRNA
expression showed higher induction after 6 h of estradiol
treatment. The pure anti-estrogen ICI 182,780 at 1 µM
inhibited PHLDA1 mRNA expression and completely abol-
ished the effects of 10 nM 17ß-estradiol on PHLDA1 ex-
pression (P < 0.05). These findings provide evidence that
PHLDA1 is regulated by estrogens and indicate that the
Figure 2. Effects of 17ß-estradiol and ICI 182,780 on PHLDA1 expression in MCF-7
breast cancer cells. MCF-7 cells were treated with 10 nM 17ß-estradiol and/or 1 µM ICI
182,780 for 2, 6, and 24 h. C = cells maintained in normal serum; ST = cells maintained
in treated serum; E2 = cells maintained in ST and containing 10 nM 17ß-estradiol; ICI =
cells maintained in ST and containing 1 µM ICI 182,780; ICI + E2 = cells maintained in
ST and containing 1 µM ICI for 1 h prior to 10 nM E2 addition. The height of the columns
indicate mean ± SEM of three independent experiments. *P ≤ 0.05 compared to cells
maintained in ST (Student t-test). RNA expression value = 1 indicates no difference of
mRNA expression, values <1 indicate down-regulation of mRNA expression and values
>1 indicate up-regulation of mRNA expression.
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mechanism of its regulation is ER-dependent.
Programmed cell death, or apoptosis, is a very well-
controlled process, which is critical to maintain tissue
homeostasis and to prevent the accumulation of damaged
cells. Defects in apoptosis play important roles in tumor
pathogenesis, allowing neoplastic cells, as well as geneti-
cally unstable cells, to survive (20). Constitutive PHLDA1
expression was associated with reduced cell growth and
colony formation, and increased basal apoptosis in the 293
melanoma cell line (13). Neef and co-workers (13) also
showed that down-regulation of PHLDA1 expression is
associated with the progression of malignant melanomas.
PHLDA1 transcripts were also identified as being down-
regulated in primary breast tumors compared to normal
breast tissue (9). More recently, using immunohistochem-
istry in tissue microarray containing a large series of
samples, we demonstrated that PHLDA1 expression is
frequently down-regulated in primary breast tumors and
that the expression of PHLDA1 irrespective of ER positivity
is a marker of good prognosis in primary breast tumors
(14). The estrogens act via their receptors stimulating cell
growth and differentiation in the mammary gland. Although
estrogens promote cell proliferation, their effect on PHLDA1
expression might be important for the process of breast
differentiation and might protect normal breast cells from
uncontrolled proliferation.
Many genes are regulated by estrogens, and the inves-
tigation of how these genes are regulated and their role in
breast cancer development may improve the identification
of new markers that in the future may benefit patients who
are under hormone therapy. Although further clinical and
experimental studies are required to better understand the
role played by PHLDA1 in normal mammary glands and in
breast cancer, our data demonstrated that PHLDA1 is an
estrogen target gene.
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